Trace-ability, Inc.

SANTA MONICA, CA 90405

SBIR Award Summary

Total Number of Awards 4
Total Value of Awards $1.9MM
First Award Date 01/01/15
Most Recent Award Date 01/01/17

Key Personnel

Last Name Name Awards Contact
ELIZAROV ARKADIJ ELIZAROV 2
SADEGHI SAMAN SADEGHI 1
Lebedev Artem Lebedev 4 Message

4 Awards Won

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-15-269
Budget: 01/01/17 - 12/31/18

Project Summary Positron Emission Tomography (PET) is regarded as a standard of care in the management of multiple types of cancer. Availability of this procedure relies on a steady supply of a radioactive contrast agent [F- 18]Fluoro-2-deoxy-d-glucose (FDG). Due to the inherent short half-life (110 min), multiple batches of FDG are typically p...

Phase 2 SBIR

Agency: National Science Foundation
Topic: MI
Budget: 03/01/16 - 02/28/18

This Small Business Innovation Research Phase II project aims to deliver a cost-effective automated quality control (QC) system for manufacturing of radioactive drugs used in Positron Emission Tomography (PET). This system will replace current QC procedures, which involve 18 manual operations, 8 visual assessments, 6 devices, and 8 samples of ra...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-14-071
Budget: 02/06/15 - 07/31/15

DESCRIPTION (provided by applicant): Positron Emission Tomography (PET) is a medical imaging modality widely used in cancer diagnostics. Oncological applications of PET include treatment planning, tumor staging and treatment efficacy evaluation. Availability of the procedure is limited by the supply of a short-lived radioactive contrast agent (1...

Phase 1 SBIR

Agency: National Science Foundation
Topic: MI
Budget: 01/01/15 - 12/31/15

This Small Business Innovation Research Phase I project will enable a disruptive technology that increases the efficiency and capacity of nuclear pharmacies that supply imaging tracers for Positron Emission Tomography (PET). PET represents the most powerful medical imaging modality, yet its availability is severely limited by the nuclear pharmac...